This research is being done to learn about the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer. Sutent® (sunitinib malate) is approved by the Food and Drug Administration (FDA) for the treatment of adults with kidney cancer. It is not approved for use in prostate cancer. The FDA is allowing the use of Sutent® (sunitinib malate) in this research study.
Subjects must be male and 18 years of age or older with Advanced Adenocarcinoma of the Prostate (specific features listed in eligibility). Subjects can not have metastatic disease. ECOG performance status of 0-1. Patients must meet certain criteria to be determined through routine blood draws. Subjects must not have had any prior VEGFR/PDGFR inhibitor or any other investigational therapy. Subject must not have any uncontrolled cardiac condition, HIV, alcoholism, hepatitis, or liver disease.
|Recruitment Contact Name:||Shirl DiPasquale, RN|
Location of Study Visits:
Study will provide compensation: No